Porphyrin-Based Drug-Delivery Nanoparticles for Photodynamic Therapy and Photoactivated Cascade Chemotherapy

Abstract

To address the systemic toxicity of the chemotherapeutic drug doxorubicin (DOX) and improve its targeted delivery efficiency for leukemia treatment, this study developed a folic acid (FA) receptor-targeted, photo-responsive nanodrug delivery system. The system was examined for its in vitro and in vivo antitumor performance against the K562 leukemia cell line. The core of this platform is a mesoporous covalent organic framework (COF), THPP TK , synthesized through the following steps: (1) preparation of a singlet oxygen ( 1 O 2 )-sensitive thioketal (TK) linker; (2) formation of the THPP TK COF via esterification between TK and 5,10,15,20-tetrakis(4hydroxyphenyl)porphyrin (THPP); (3) surface modification of THPP TK using FAconjugated polyethylene glycol (FA-PEG), acting as both a reaction terminator and hydrophilic coating; (4) loading of DOX into the COF mesopores to obtain the final nanodrug DOX@THPP TK -PEG-FA. This system employs a dual photoactivation process: under 660 nm laser irradiation, the THPP component generates 1 O 2 for photodynamic therapy (PDT), while also initiating cleavage of the TK linker to enable controlled release of DOX for chemotherapy (CT). This cascade mechanism strengthens the overall antitumor response. Studies in a Balb/c nude mouse subcutaneous xenograft model using K562 cells confirmed the nanosystem's strong tumor-targeting ability, notable in vitro and in vivo antitumor activity, and reduced DOX-associated systemic toxicity.

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
09 Dec 2025
Accepted
22 Dec 2025
First published
23 Dec 2025

J. Mater. Chem. B, 2026, Accepted Manuscript

Porphyrin-Based Drug-Delivery Nanoparticles for Photodynamic Therapy and Photoactivated Cascade Chemotherapy

L. Du, K. Zeng, H. Huang and H. He, J. Mater. Chem. B, 2026, Accepted Manuscript , DOI: 10.1039/D5TB02747K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements